Regional differences in serotonin content in the nucleus of the solitary tract of male rats after hypovolemia produced by polyethylene glycol

J. Thomas Curtis · Michael B. Anderson · Kathleen S. Curtis

Received: 30 June 2012 / Accepted: 6 August 2012 / Published online: 4 September 2012
© The Physiological Society of Japan and Springer 2012

Abstract Serotonin (5-HT) has been implicated in centrally mediated compensatory responses to volume loss in rats. Accordingly, we hypothesized that slowly developing, non-hypotensive hypovolemia increases serotonin in the hindbrain nucleus of the solitary tract (NTS). We produced volume loss in adult male rats by administering hyperoncotic polyethylene glycol (PEG) and then assessed 5-HT levels in the NTS using measurements of tissue 5-HT content or 5-HT immunohistochemistry. The results show selective increases of 5-HT in the caudal NTS after PEG treatment, but no change in the primary 5-HT metabolite, 5-HIAA. Moreover, the intensity of 5-HT immunolabeled fibers in the caudal NTS was increased after PEG treatment. These findings suggest that, after PEG-induced hypovolemia, 5-HT accumulates in neural elements in the caudal NTS. We propose that this accumulation is attributable to an initial release of 5-HT that then acts at presynaptic autoreceptors to inhibit subsequent 5-HT release.

Keywords: Baroreflex pathway · Hemorrhage · 5-HIAA · Norepinephrine

Introduction

Changes in body fluid volume elicit compensatory behavioral and physiological responses which, collectively, serve to maintain or restore blood volume to optimal levels. Some of these responses, such as water intake, salt intake, and hormonal responses, occur over a comparatively long period of time, whereas changes in autonomic nervous system activity occur in a much shorter time frame. Short-term responses, in particular, involve low pressure baroreceptors in the heart and great veins which signal increased or decreased volume, and subsequently activate hindbrain baroreflex pathways, the connectivity and neurochemistry of which are well defined (for review, see [1]). Activation in these pathways has been reported in response to increased volume [2–4] and, perhaps more familiarly, in response to decreased volume [5–8], such as that produced by experimental hemorrhage. Despite some overlap, however, studies by Badoer and colleagues [9–11] show that subpopulations of neurons within these hindbrain areas that project to specific targets appear to be selectively activated by hypovolemia.

The neurochemical profile of hindbrain neurons activated by hypovolemia is the subject of disagreement and conflicting findings. To some extent, the discrepant findings may be a consequence of the use of hemorrhage to produce volume loss, as severe hemorrhage is typically accompanied by hypotension. In fact, the pattern of activity produced by substantial volume loss [5–8] is remarkably similar to that observed after decreased blood pressure [5–7, 12]. Several investigators have reported that neurons in the A1 and A2 catecholaminergic areas of the hindbrain are activated by severe, hypotensive hemorrhage and by decreased blood pressure, but not by smaller, non-hypotensive hemorrhage [7, 13]. It is possible that differential activation of these neurons by hypotensive and non-hypotensive hemorrhage depends on the degree of hypovolemia, but this idea has been difficult to test, as greater hemorrhage tends to elicit hypotension. In a previous study [14], we circumvented this dilemma by using a hyperoncotic solution of polyethylene glycol (PEG), which produces...
slowly developing [15, 16] volume loss that is isosmotic [16, 17] and non-hypotensive [18, 19]. We combined this approach with immunocytochemical techniques to label hindbrain neurons for the fos protein, a marker of neural activation, and dopamine-β-hydroxylase, the enzyme required to convert dopamine to norepinephrine (NE), and found that A1 and A2 neurons were not activated by PEG despite substantial (~15–20 %) volume loss. These findings complement reports that A1 and A2 neurons were not activated by non-hypotensive hemorrhage (7, 13, but see [20]), and, taken together, suggest that NE-containing neurons in the hindbrain are involved in responses to decreased blood pressure but not to decreased blood volume. Thus, activation in hindbrain pathways in response to volume loss may involve a different neurotransmitter.

Much research has focused on serotonin (5-HT) involvement in the activation of hindbrain baroreflex pathways during hypovolemia. Results to date suggest that 5-HT influences activity in the nucleus of the solitary tract (NTS); however, disagreement exists as to whether 5-HT increases or decreases compensatory blood pressure and/or heart rate responses to hypovolemia. Some studies used severe hemorrhage to investigate 5-HT-mediated compensatory responses (e.g., [21, 22]), while others used pharmacological manipulations to examine 5-HT effects (e.g., [23–27]). Thus, the conflicting findings may be attributable to the hypotension that accompanies severe hemorrhage, to 5-HT receptor subtype specific effects, or to both. The goal of the present study was to assess hypovolemia-induced activation of 5-HT in the NTS while minimizing these confounds. In addressing this goal, two issues were critical: first, separating hypovolemia from hypotension, and thereby eliminating the possibility that hypotension contributes to the findings; and second, reducing the possibility of effects attributable to administration of specific 5-HT agonists or antagonists. Accordingly, we produced volume loss by administering PEG and then examined levels of 5-HT in the NTS using measurements of tissue 5-HT content and 5-HT immunohistochemistry.

Methods

Animals

Adult male Sprague–Dawley rats (Charles River) weighing 400–650 g (i.e., 3.5–6 months of age) at the time of testing were individually housed in a temperature-controlled colony room on a 12:12-h dark:light cycle (lights on at 0700 hours) with ad libitum access to deionized water and standard laboratory chow (Purina #5001) except as noted. Experimental protocols were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals; procedures were approved by the Florida State University (measurement of 5-HT content in brain tissue) and the Oklahoma State University (5-HT immunohistochemistry in brain sections) Animal Care and Use Committees.

PEG-induced hypovolemia

On the morning of the test day (0800–1000 hours), rats were removed from their cages, weighed, and injected s.c. with 5 ml of PEG (8,000 MW, 40 % w/v in 0.15 M NaCl; Fisher Scientific) or 5 ml of the 0.15 M NaCl vehicle (VEH). Rats were then returned to their cages, from which water and chow had been removed. As in our previous study [14], we waited 6 h to ensure that substantial hypovolemia had developed, and then deeply anesthetized rats with sodium pentobarbital (50 mg/rat, ip; Abbot Laboratories). As described in the following, blood was collected for determination of plasma protein concentration and hematocrit; brains were collected for determination of tissue 5-HT content or for 5-HT immunolabeling.

Tissue 5-HT content

Following VEH (n = 7) or PEG (n = 8) treatment and anesthesia as described, rats were decapitated, brains were rapidly removed, frozen on dry ice, and then transferred to a −80 °C freezer. Trunk blood was collected into microcapillary tubes and centrifuged to evaluate plasma protein concentration using a refractometer, and hematocrit using a hematocrit reader.

Hindbrains were cut into 300-µm sections using a cryostat and transferred to a cold microscope slide. A blunted 18-g needle was used to collect bilateral tissue punches (838 µm diameter) from two levels of the NTS [28]: caudal to calamus scriptorius (~14.30 to ~14.60 mm relative to bregma, which we defined as cNTS); and at the level of the Area Postrema between calamus scriptorius and obex (~13.70 to ~14.00 mm relative to bregma, which we defined as mNTS). For each animal, the two punches from each level were combined in a single microcentrifuge tube and then transferred to a −80 °C freezer until processed for analysis of tissue content of 5-HT, 5-hydroxyindoleacetic acid (5-HIAA; the primary metabolite of 5-HT), and NE using high performance liquid chromatography. Sections from which punches were taken were examined using darkfield microscopy to verify that punches were located in cNTS and mNTS.

Tissue punches were sonicated in 75 µl of 0.1 N perchloric acid. After centrifugation at 10,000g for 10 min, the supernatant was removed and the remaining pellet was retained for total protein assay. The supernatant was further purified by centrifugation through 0.2-µm filters prior to
measurement of 5-HT, 5-HIAA, and NE. Separation of analytes was achieved using a Waters Separation Module (Waters), an HD-150 column (ESA), and mobile phase (0.7 ml/min) consisting of 75 mM sodium dihydrogen phosphate monohydrate (EM Science), 1.7 mM 1-octane-sulfonic acid sodium salt (Sigma), 0.01 % triethylamine (Aldrich), 25 μM EDTA (Fisher Scientific), and pH adjusted to 3.0 with 85 % phosphoric acid (Fisher Scientific). Measurement was via electrochemical detection (ESA). For each sample, 10 μl was injected on column. Separated samples then were oxidized at 400 mV, followed by reduction at 350 mV. 5-HT and 5-HIAA were quantified from oxidation peaks, while NE was quantified from a reduction peak. Peak areas were converted to pg of analyte/10 μl supernatant by comparison with a standard curve calculated using standards of known concentration.

Protein content of tissue pellets was measured using a Pierce BCA Protein Assay Kit (Pierce). Tissue pellets were re-suspended in assay buffer and 10 μl of each sample was aliquoted into 96-well plates in duplicate with 200 μl of BCA solution added to each well. Plates were incubated for 30 min at 60 °C. Sample absorbance was then measured at 562 nm using a plate spectrophotometer (Molecular Devices). Protein amount was expressed as equivalents of bovine serum albumen, known amounts of which served as standards against which unknowns were compared. Duplicates were averaged to obtain the protein content for each sample.

To control for possible differences in the size of tissue punches, 5-HT, 5-HIAA, and NE content were expressed as a function of the total protein content of the tissue punch. The relationship between tissue 5-HT and the metabolite was further assessed by examining the ratio between 5-HT and 5-HIAA, calculated as (5-HT/μg protein)/(5-HIAA/μg protein).

5-HT immunolabeling

Following VEH (n = 5) or PEG (n = 6) treatment and anesthesia as described, blood samples were taken from the heart for later evaluation of plasma protein concentration and hematocrit. Immediately after blood samples were collected, rats were perfused transcardially with ice-cold 0.15 M NaCl followed by cold 4 % paraformaldehyde. Brains were removed, post-fixed in paraformaldehyde overnight at 4 °C, and then transferred to a 30 % sucrose solution until cut into a 1.3 series of 40-μm sections using a cryostat. Sections were stored in a cryoprotectant solution [29] at −20 °C.

One series of free-floating sections through the hindbrain from each rat injected with VEH or PEG was processed for immunolabeling of 5-HT. Briefly, sections were rinsed in 0.5 M Tris-NaCl, incubated for 30 min in a 0.5 % solution of H2O2, rinsed again, and then soaked in 10 % normal goat serum (NGS) mixed in 0.5 M Tris-NaCl with 0.5 % Triton-X. Sections were incubated in the 5-HT primary antibody (rabbit anti-5HT; Biogenex, PU068-UP) diluted 1:1,000 in 2 % NGS at 4 °C for 70 h. Sections were rinsed in 2 % NGS and then incubated in the secondary antibody (Cy2; goat anti-rabbit IgG; Jackson Immunoresearch) diluted 1:300 in 2 % NGS at room temperature for 6 h. The reaction was terminated by rinses with 2 % NGS.

Sections then were ordered, mounted on slides, and allowed to air-dry. Slides were dehydrated in 70, 95, and 100 % EtOH (3 min/concentration), defatted in xylenes (5 min × 2), and then coverslipped.

An epifluorescent microscope (Nikon Eclipse 80i) equipped with a camera and FITC filter was used to visualize 5-HT immunolabeling in 2–3 representative sections, matched between subjects, from the cNTS (−14.20 to −14.60 mm relative to bregma) and from mNTS (−13.60 to −14.10 mm relative to bregma). Digital photomicrographs of each section were taken, holding exposure time constant. Areas of low 5-HT immunolabeling in each section were identified; these areas, typically in the ventral portions of the sections, were used to subtract background labeling from the images using NIS Elements imaging software (Nikon). Based on landmarks [28], cNTS and mNTS were outlined, and the area of each outlined region and the intensity of the fluorescent labeling within the region were determined using NIS Elements. For each section, intensity was normalized to area (calculated as intensity/μm²) and the average normalized intensity for each level (cNTS and mNTS) was calculated for each rat. Group mean normalized intensities then were calculated for cNTS and mNTS.

Statistical analyses

Data are shown as group means ± SEM. Differences in plasma protein concentration and hematocrit were assessed separately for the two experiments (tissue 5-HT content and 5-HT immunolabeling) using independent t tests. Hematocrits were used to calculate % change in plasma volume for each experiment (modified from [30]) as 100 × [(100-hematocritPEG) − (100-hematocritmean VEH)]/(100-hematocritmean VEH). Independent t tests then were used to compare calculated volume loss between the two experiments.

Differences in tissue 5-HT, 5-HIAA, NE, the 5-HT:5-HIAA ratio, and the intensity of 5-HT immunolabeling were assessed using 1-way ANOVAs (Statistica; StatSoft); statistically significant (p < 0.05) effects were further evaluated using Fisher’s LSD tests.

Results

In both experiments (tissue 5-HT content, 5-HT immunolabeling), PEG caused significant increases in plasma
Percent change in plasma volume was calculated as 100 × [(100-hematocrit$_{PEG}$) − (100-hematocrit$_{mean VEH}$)]/(100-hematocrit$_{mean VEH}$)

Within an experiment, ** significantly greater than VEH ($p < 0.001$), * significantly greater than VEH ($p < 0.01$)

### Table 1

| Weight (g) | Hematocrit (%) | Change in volume (%) | Plasma protein concentration (g/dL) |
|-----------|----------------|----------------------|-----------------------------------|
| VEH       | 461.8 ± 49.4   | 45.2 ± 0.5           | 6.0 ± 0.2                         |
| PEG       | 493.7 ± 39.9   | 54.5 ± 1.8**         | 8.4 ± 0.2**                       |
| 5-HT immunolabeling |          |                      |                                   |
| VEH       | 544.4 ± 25.4   | 45.3 ± 0.7           | 5.9 ± 0.1                         |
| PEG       | 513.8 ± 20.6   | 52.3 ± 1.1*          | 7.6 ± 0.3**                       |

The major findings in this study were that non-hypotensive hypovolemia produced by PEG increased tissue 5-HT content in the NTS and, more specifically, within the caudal portion of the NTS (cNTS). The intensity of the immunolabeling was also greater in the cNTS of PEG-treated rats compared to that in the mNTS. Surprisingly, however, the intensity of labeling in the cNTS of VEH-treated rats was not different from that in the cNTS after PEG treatment. It is possible that greater levels of 5-HT fiber labeling at higher magnification.

### Discussion

Despite the consensus that 5-HT is involved in centrally mediated responses to volume loss [32, 33], it has been difficult to arrive at a coherent picture of the specific role of 5-HT in hindbrain baroreflex pathways. In part, this difficulty has arisen from the use of hypotensive hemorrhage to produce volume loss (e.g., [34–36]), as it is difficult to separate effects attributable to volume loss from those attributable to hypotension. Another complication involves experimental manipulations that employed selective 5-HT receptor agonists and antagonists [23–26], with the resultant receptor subtype-specific effects. Therefore, in evaluating the role of 5-HT in the NTS, we sought to minimize the hypotension that accompanies rapid, severe hemorrhage by using PEG treatment to produce gradual non-hypotensive, isomotic volume loss [16–19]. To ensure that substantial hypovolemia had developed, we imposed a 6-h delay after PEG treatment (Table 2; see also [15, 31]). This delay also facilitated comparisons with our previous study [14], in which comparable volume loss was produced.

The major findings in this study were that non-hypotensive hypovolemia produced by PEG increased tissue 5-HT content in the NTS and, more specifically, within the caudal portion of the NTS (cNTS). The intensity of the immunolabeling was also greater in the cNTS of PEG-treated rats compared to that in the mNTS. Surprisingly, however, the intensity of labeling in the cNTS of VEH-treated rats was not different from that in the cNTS after PEG treatment. It is possible that greater levels of

### Tissue 5-HT content

Figure 1 (top) shows that there was a significant difference in tissue 5-HT content in the NTS ($F_{3,19} = 3.447, p < 0.05$). Pairwise comparisons revealed that 5-HT in the cNTS of rats that were treated with PEG was significantly greater than that in the cNTS of rats that were treated with VEH ($p < 0.05$), as well as that in the mNTS of VEH-treated rats ($p < 0.05$). However, 5-HT in the cNTS of rats that were treated with PEG was not different from that in the mNTS of PEG-treated rats. 5-HT levels in the mNTS of VEH-treated rats were comparable.

Figure 2 shows 5-HT immunolabeling in the cNTS of a VEH-treated rat and a PEG-treated rat. As shown in Fig. 3, there was a significant difference in the intensity of 5-HT immunolabeling among the groups ($F_{3,18} = 5.736, p < 0.01$). Pairwise comparisons revealed that the intensity of labeling in the cNTS of rats that were treated with PEG was greater than that in the mNTS of rats that were treated with PEG or with VEH (both $p < 0.01$), which, in turn, were not different from each other. The intensity of 5-HT immunolabeling in the cNTS of VEH-treated rats was intermediate and did not differ from any of the other groups. Figure 4 shows digital photomicrographs of the 5-HT fiber labeling at higher magnification.
variability in 5-HT immunolabeling in the cNTS of VEH-treated rats prevented the detection of a meaningful difference, or that immunolabeling does not provide the degree of sensitivity obtained with direct measurement of tissue content using HPLC. In either case, we were able to detect differences in 5-HT immunolabeling between the cNTS and mNTS of PEG-treated rats, and the intensity of the immunolabeling was greater in the cNTS. Thus, increased 5-HT in the NTS after PEG-induced hypovolemia was not simply due to a generalized increase in 5-HT. Rather, differences in both tissue 5-HT content and immunolabeling intensity were specific to the cNTS. In addition, there were no changes in tissue NE in the cNTS or the mNTS, suggesting that PEG treatment did not have non-specific effects within the NTS. Thus, non-hypotensive hypovolemia has regionally selective effects to increase 5-HT in the cNTS.

Based on previous studies of 5-HT in the NTS [23–27, 37], we expected that PEG treatment would stimulate release of 5-HT in the NTS. However, there was no change in tissue levels of the 5-HT metabolite 5-HIAA (which would be expected to increase), and an increase in the 5-HT to 5-HIAA ratio (which would be expected to decrease) if elevated 5-HT were due to increased release [46]. Thus, the increase in 5-HT may be due to increased accumulation of intracellular 5-HT, rather than to increased 5-HT release. In this regard, closer examination of the 5-HT immunolabeling (Fig. 4) shows the beaded appearance of the labeling—i.e., varicosities—suggestive of terminal boutons and/or en passant synapses. Clearly, immunolabeling alone does not allow conclusive determination of whether 5-HT release was affected; on the other hand, it affords a high degree of spatial resolution that, in conjunction with evidence from HPLC of increased tissue 5-HT without changes in the metabolite, provides important information about the increased 5-HT. Taken together, the tissue content and immunolabeling results are consistent with the accumulation of 5-HT in neural elements and, in particular, in synaptic specializations located on neural fibers that terminate in or pass through the cNTS. Typically, the 5-HT would be thought to originate from one of the brainstem raphe cell groups, and, in fact, the NTS does receive projections from raphe 5-HT cell groups (e.g., [34, 35]). Moreover, severe hypotensive hemorrhage accompanied by hypercapnia activates 5-HT neurons in some raphe cell groups [34–36]. Nonetheless, several findings suggest an additional source. First, vagal afferent input arising from low pressure baroreceptors terminates in the NTS, including in the region caudal to the Area Postrema [38–40]. More importantly,
vagal afferents that terminate in the NTS include serotonergic fibers [26, 37], and some NTS neurons that respond to vagal cardiopulmonary input also respond to local application of 5-HT [23, 27]. These observations, in conjunction with the present finding of increased 5-HT specific to the cNTS, suggest that 5-HT of vagal origin may also contribute to compensatory responses to volume loss, and ongoing studies are addressing this possibility.

In the present study, both the immunolabeling and the direct assessment of tissue content clearly demonstrate that 5-HT increased in the cNTS during gradual, non-hypotensive volume loss. Importantly, there was no increase in tissue levels of the metabolite, suggesting that 5-HT accumulated intracellularly. This accumulation could arise if reuptake of 5-HT via the serotonin transporter (SERT) occurs more rapidly than does metabolism to 5-HIAA; however, reports that SERT is downregulated by 5-HT (e.g., [41]) are at odds with this possibility. Instead, we believe our data suggest that accumulation results from the inhibition of 5-HT release. Given the increase in 5-HT levels we observed (~1.5- to 3.5-fold increase; see Figs. 1, 3), inhibition of basal release seems unlikely to account for the increase, especially without a concomitant increase in synthesis. At the same time, increased synthesis of 5-HT and its subsequent transport to axon terminals in the NTS...
would not be expected in the absence of neural activation. These observations lead to the intriguing possibility that, during the early stages of PEG-induced hypovolemia (detailed in, e.g., [15, 16]), 5-HT neurons are activated and 5-HT release is stimulated, but that as the hypovolemia develops and persists (Table 1: [14–17, 31]), further release is inhibited. This phenomenon of activation followed by inhibition has been observed in other 5-HT systems (for review, see [42]). Hence, we suggest that PEG-induced hypovolemia initially stimulates 5-HT release and, with it, an increase in 5-HT synthesis. However, when hypovolemia is prolonged, 5-HT release is inhibited while 5-HT synthesis remains temporarily elevated. Together, these events would be expected to increase intracellular levels of 5-HT but have no affect on (or tend to increase) extracellular levels of 5-HIAA, as we observed.

Inhibition of 5-HT release may seem contradictory given reports of cardiovascular and/or sympathetic effects after site-specific administration of 5-HT agonists into the NTS [24–26]. However, timing may be a critical aspect in understanding these findings. Schadt [33] has proposed that different neural mechanisms underlie different phases of hemorrhage and that 5-HT may be more important during the later-occurring, decompensated phase—the global sympathoinhibition and hypotension that occur after a hemorrhage that reduces blood volume by ~25–30% (see also [35]). Activation of 5-HT1A receptors prevents or delays the decompensated phase [21, 22], and several lines of evidence suggest that at least some of these receptors are autoreceptors that inhibit subsequent 5-HT release [43, 44]. Therefore, based on the results of these initial studies and in conjunction with previous findings, we propose that the early stage of developing PEG-induced hypovolemia stimulates an initial release of 5-HT that has dual effects. First, 5-HT produces neural activation in the NTS that leads to compensatory cardiovascular and sympathetic responses (e.g., [24–26, 45–47]). Second, 5-HT activates inhibitory presynaptic autoreceptors, thereby reducing subsequent release [43, 44] but without initially affecting ongoing 5-HT synthesis. As a result, 5-HT accumulates in neural fibers 6 h after PEG treatment. It is possible that such a ‘shift’ in 5-HT release may underlie the shift from the compensated to the decompensated phase of sympathetic responses to hemorrhage. We are not aware of any studies that have specifically addressed this proposed idea, though our findings that PEG increased 5-HT without increasing 5-HIAA are consistent with it. Nonetheless, it is clear that thorough assessment of the role of 5-HT in non-hypotensive hypovolemia will require additional studies to systematically examine the time course of changes in 5-HT and 5-HIAA, and the functional consequences of such changes.

In conclusion, hypovolemia produced by PEG selectively increased 5-HT in the caudal portion of the NTS, but not in the NTS at the level of the Area Postrema. On the surface, these observations would seem to be consistent with increased release of 5-HT within the cNTS in response to non-hypotensive hypovolemia, particularly given reports of serotonergic, but not catecholaminergic, involvement in compensatory responses to volume loss in rats [23, 26, 37, 47, 48]. However, a different conclusion emerges when tissue 5-HT content and 5-HT immunolabeling—two different, though complementary, measures—are considered together. Increased 5-HT immunolabeling and increased tissue 5-HT content, along with the absence of changes in the metabolite, 5-HIAA, raise the possibility that 5-HT release was inhibited by PEG-induced hypovolemia.

Acknowledgments Portions of these data were presented at the annual meeting of the Society for Neuroscience (Washington, DC: 2005). Grants from the National Institute on Deafness and Communication Disorders DC-06360 (K.S.C.), the National Institute for Child Health and Development HD-48462 (J.T.C.), the Oklahoma Center for the Advancement of Science and Technology Health Research Program HR 09-123 (K.S.C.), and Oklahoma EPSCoR (M.B.A.) supported this research. The authors thank Drs. Rob Conteras, Zuoxin Wang, and Marc Freeman for their generosity with equipment and expertise and Ms. De’Nise McKee for technical advice and assistance.

Conflict of interest The authors declare that they have no conflict of interest.

References

1. Dampney RA (1994) Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 74:323–364
2. Narvaez JA, Covenas R, de Leon M, Aguirre JA, Cintra A et al (1993) Induction of c-fos immunoreactivity in tyrosine hydroxylase and phenylethanolamine-N-methyltransferase immunoreactive neurons of the medulla oblongata of the rat after phosphate-buffered saline load in the urethane-anaesthetized rat. Brain Res 602:342–349
3. Badoer E, McKinlay D, Trigg L, McGrath BP (1997) Distribution of activated neurons in the rabbit brain following a volume load. Neuroscience 81:1065–1077
4. Randolph RR, Li Q, Curtis KS, Sullivan MJ, Cunningham JT (1998) Fos expression following isotonic volume expansion of the unanaesthetised male rat. Am J Physiol 274:R1345–R1352
5. Chan RK, Sawchenko PE (1994) Spatially and temporally differentiated patterns of c-fos expression in brainstem catecholaminergic cell groups induced by cardiovascular challenges in the rat. J Comp Neurol 348:433–460
6. Krukoff TL, Mactavish D, Jhamandas JH (1997) Activation by hypotension of neurons in the hypothalamic paraventricular nucleus that project to the brainstem. J Comp Neurol 385:285–296
7. Krukoff TL, MacTavish D, Harris KH, Jhamandas JH (1995) Changes in blood volume and pressure induce c-fos expression in brainstem neurons that project to the paraventricular nucleus of the hypothalamus. Brain Res Mol Brain Res 34:99–108
8. Dun NJ, Dun SL, Chiaia NL (1993) Hemorrhage induces Fos immunoreactivity in rat medullary catecholaminergic neurons. Brain Res 608:223–232
9. Badoer E, McKinley MJ, Oldfield BI, McAllen RM (1993) A comparison of hypotensive and non-hypotensive hemorrhage on Fos expression in spinally projecting neurons of the paraventricular nucleus and rostral ventrolateral medulla. Brain Res 610:216–223
10. Badoer E (1998) Neurons in the hypothalamic paraventricular nucleus that project to the rostral ventrolateral medulla are not activated by hypotension. Brain Res 801:224–227
11. Badoer E, Merolli J (1998) Neurons in the hypothalamic paraventricular nucleus that project to the rostral ventrolateral medulla are activated by haemorrhage. Brain Res 791:317–320
12. Schlitz JC, Hoffman GE, Stricker EM, Sved AF (1997) Decreases in arterial pressure activate oxytocin neurons in conscious rats. Am J Physiol 273:R1474–R1483
13. Buller KM, Smith DW, Day TA (1999) Differential recruitment of hypothalamic neuroendocrine and ventrolateral medulla catecholamine cells by non-hypotensive and hypotensive hemorrhages. Brain Res 834:42–54
14. Curtis KS, Krause EG, Contreras RJ (2002) Fos expression in non-catecholaminergic neurons in medullary and pontine nuclei after volume depletion induced by polyethylene glycol. Brain Res 948:149–154
15. Stricker EM, Jalowiec JE (1970) Restoration of intravascular fluid volume following acute hypovolemia in rats. Am J Physiol 218:191–196
16. Stricker EM, Vagnucci AH, McDonald RH Jr, Leenen FH (1979) Renin and aldosterone secretions during hypovolemia in rats: relation to NaCl intake. Am J Physiol 237:R45–R51
17. Stricker EM, Verbalis JG (1986) Interaction of osmotic and volume stimuli in regulation of neurohypophysial secretion in rats. Am J Physiol 250:R267–R275
18. Stricker EM, Schreinhofer AM, Verbalis JG (1994) Sodium deprivation blunts hypovolemia-induced pituitary secretion of vasopressin and oxytocin in rats. Am J Physiol 267:R1336–R1341
19. Schreinhofer AM, Stricker EM, Sved AF (1994) Chronic nucleus tractus solitarius lesions do not prevent hypovolemia-induced vasopressin secretion in rats. Am J Physiol 267:R965–R973
20. Smith DW, Day TA (2003) Catecholamine and oxytocin cells respond to hypovolaemia as well as hypotension. NeuroReport 14:1493–1495
21. Scrogin KE, Veelken R, Johnson AK (1998) Central methysergide prevents renal sympathoinhibition and bradycardia during hypotensive hemorrhage. Am J Physiol 274:H43–H51
22. Scrogin KE (2003) 5-HT1A receptor agonist 8-OH-DPAT acts in the hindbrain to reverse the sympatholytic response to severe hemorrhage. Am J Physiol Regul Integr Comp Physiol 284:R782–R791
23. Sevoz-Couche C, Wang Y, Ramage AG, Spyer KM, Jordan D (2000) In vivo modulation of nucleus tractus solitarius (NTS) neurones by activation of 5-hydroxytryptamine(2) receptors in rats. Neuropharmacology 39:2006–2016
24. Comet MA, Laguzzi R, Hamon M, Sevoz-Couche C (2005) Functional interaction between nucleus tractus solitarii NK1 and 5-HT3 receptors in the inhibition of baroreflex in rats. Cardiovasc Res 65:930–939
25. Nosjean A, Callera JC, Bonagamba L, Machado B, Hamon M et al (2002) Serotonin3(3) receptor stimulation in the nucleus tractus solitarii activates non-catecholaminergic neurons in the rat ventrolateral medulla. Neuroscience 112:935–949
26. Merah N, Orer HS, Laporte AM, Gozlan H, Hamon M et al (1992) Baroreceptor reflex inhibition induced by the stimulation of serotonin3 receptors in the nucleus tractus solitarii of the rat. Neuroscience 46:91–100
27. Jeggo RD, Kellett DO, Wang Y, Ramage AG, Jordan D (2005) The role of central 5-HT3 receptors in vagal reflex inputs to neurones in the nucleus tractus solitarius of anaesthetized rats. J Physiol 566:939–953
28. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, San Diego
29. Watson RE Jr, Wiegand SJ, Clough RW, Hoffman GE (1986) Use of cryoprotectant to maintain long-term peptide immunoreactivity and tissue morphology. Peptides 7:155–159
30. Greenleaf JE, Convertino VA, Mangseth GR (1979) Plasma-volume during stress—osmolality and red-cell volume. Med Sci Sports Exercise 11:99
31. Stricker EM (1966) Extracellular fluid volume and thirst. Am J Physiol 211:232–238
32. Cote F, Filgny C, Fromes Y, Mallet J, Vodjdani G (2004) Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med 10:232–238
33. Schadt JC (2003) What is the role of serotonin during hemorrhage in conscious animals? Am J Physiol Regul Integr Comp Physiol 284:R780–R781
34. Kung LH, Scrogin KE (2011) Serotonin nerve terminals in the dorsomedial medulla facilitate sympathetic and ventilatory responses to hemorrhage and peripheral chemoreflex activation. Am J Physiol Regul Integr Comp Physiol 301:R1367–R1379
35. Kung LH, Glasgow J, Ruszaj A, Gray T, Scrogin KE (2010) Serotonin neurons of the caudal raphe nuclei contribute to sympathetic recovery following hypotensive hemorrhage. Am J Physiol Regul Integr Comp Physiol 298:R939–R953
36. Pelaez NM, Schreinhofer AM, Guyenet PG (2002) Decompensated hemorrhage activates serotonergic neurons in the subependymal parapyramidal region of the rat medulla. Am J Physiol Regul Integr Comp Physiol 283:R688–R697
37. Sykes RM, Spyer KM, Izzo PN (1994) Central distribution of substance P, calcitonin gene-related peptide and 5-hydroxytryptamine in vagal sensory afferents in the rat dorsal medulla. Neuroscience 59:195–210
38. Spyer KM (1982) Central nervous integration of cardiovascular control. J Exp Biol 100:109–128
39. Hines T, Toney GM, Mifflin SW (1994) Responses of neurons in the nucleus tractus solitarius to stimulation of heart and lung receptors in the rat. Circ Res 74:1188–1196
40. Paton JF (1998) Convergence properties of solitary tract neurones driven synaptically by cardiac vagal afferents in the mouse. J Physiol 508(1 Pt 1):237–252
41. Kütter K, Lau T, Schloss P (2010) Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. Eur J Pharmacol 629:63–67
42. Saito H, Matsumoto M, Togashi H, Yoshiooka M (1996) Functional interaction between serotonin and other neuronal systems: focus on in vivo microdialysis studies. Jpn J Pharmacol 70:203–205
43. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083–1152
44. Nichols DE, Nichols CD (2008) Serotonin receptors. Chem Rev 108:1614–1641
45. Dergacheva O, Kamendi H, Wang X, Pinol RA, Frank J et al (2009) 5-HT2 receptors modulate excitatory neurotransmission to cardiac vagal neurons within the nucleus ambiguus evoked during and after hypoxia. Neuroscience 164:1191–1198
46. Horiuichi J, McDowell LM, Dampney RAL (2008) Role of 5-HT1A receptors in the lower brainstem on the cardiovascular response to dorsomedial hypothalamic activation. Auton Neurosci 142:71–76
47. Kellett DO, Ramage AG, Jordan D (2005) Central 5-HT7 receptors are critical for reflex activation of cardiac vagal drive in anaesthetized rats. J Physiol 563:319–331
48. Damaso EL, Bonagamba LGH, Kellett DO, Jordan D, Ramage AG et al (2007) Involvement of central 5-HT7 receptors in modulation of cardiovascular reflexes in awake rats. Brain Res 1144:82–90